search
Back to results

Continuous Intercostal Nerve Blockade for Traumatic Rib Fractures

Primary Purpose

Rib Fractures

Status
Terminated
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
hydromorphone hydrochloride
Infusion catheter placement
bupivicaine 0.25%
bupivicaine 0.5%
Sponsored by
Anthony Iacco
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Rib Fractures focused on measuring Catheters, Indwelling, Infusion Pumps, Anesthesia, Local, Analgesia, Patient-Controlled, Bupivacaine

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Admission to trauma service at Beaumont Hospital, Royal Oak, Michigan
  • Two or more rib fractures in an anatomic pattern feasible for nerve blockade (unilateral or bilateral)
  • Age greater than or equal to 18 years
  • Ability to comprehend and endorse an informed consent

Exclusion Criteria:

  • Patients who are pregnant or breastfeeding
  • Patients intubated before placement of continuous infusion catheter
  • Any significant concomitant injuries potentially confounding for evaluation of the effectiveness of analgesia (eg., traumatic brain injury)
  • History of an allergic reaction to local anesthetic
  • Use of other regional anesthetics before evaluation (epidural or paravertebral nerve blockade)
  • International Normalized Ratio (INR) > 2.0
  • Inability to obtain informed consent

Sites / Locations

  • Beaumont Hospital - Royal Oak

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Placebo Comparator

Experimental

Experimental

Arm Label

PCA only

Bupivicaine 0.25% (LOW DOSE)

Bupivicaine 0.5% (HIGH DOSE)

Arm Description

Procedure: Standard of care - Intravenous Patient Controlled Anesthesia (PCA) 0.1 mg hydromorphone hydrochloride, every 6 minutes. Boluses of 0.1 mg IV hydromorphone for uncontrolled pain up to a maximum of 2.5 mg/hr.

Standard PCA infusion 0.1 mg hydromorphone hydrochloride, every 6 minutes. Bolus 0.1 mg hydromorphone for uncontrolled pain up to a maximum of 2.5 mg/hr. Infusion catheter placement. Bupivacaine 0.25% 4 ml/hr total for dual chamber catheter.

Standard PCA infusion 0.1 mg hydromorphone hydrochloride, every 6 minutes. Bolus 0.1 mg hydromorphone for uncontrolled pain up to a maximum of 2.5 mg/hr. Infusion catheter placement. Bupivacaine 0.5% 4 ml/hr total for dual chamber catheter.

Outcomes

Primary Outcome Measures

Narcotic Use
Quantity of systemic narcotic used (hydromorphone hydrochloride, Dilaudid) averaged per day over the length of hospital stay, in mg/24 hours.

Secondary Outcome Measures

Time to Improvement in Pulmonary Function
Determine the impact of catheter-infused medications on maximal inspiratory lung volume measured by incentive spirometer (IS) as a change from baseline at 24, 48, 72 hours and at 3 days post catheter placement or at discharge (or PCA placement in comparator group). Endpoint will be the time to improvement of vital capacity to greater than 1.4 liters (or 15 mL/kg).
Time to Improvement in Pain Intensity
Determine the impact of catheter-infused medications on self-reported pain intensity reported as a change from baseline (admission) at 24, 48, 72 hours and at 3 days post catheter placement or at discharge (or PCA placement in comparator group) on a 0-10 point Likert scale, with 0=no pain, and 10= the worst pain ever. Response will be defined as time to a decrease of at least two points on the scale.
Morbidity
Collection of complications observed at any point during the hospital admission that included randomization, including pneumothorax, hemothorax, acute respiratory distress syndrome, pneumonia, empyema, need for tracheostomy, need for mechanical ventilation, length of time on mechanical ventilation, and an assessment of the degree of association of each event with the catheter insertion procedure or with underlying trauma. Each of these outcomes will be scored as yes/no.
Mortality
All cause death, death associated with infusion catheter, within 30 days from date of randomization. This outcome will be scored as yes/no and cause of death will be collected.
Hospital Length of Stay
Integer days of inpatient admission in the hospital stay that included randomization.
Surgical Intensive Care Unit (SICU) Length of Stay
Integer days of admission to the surgical intensive care unit. For patients not requiring admission to surgical intensive care, patient is not analyzed. Usual range is 3-5 days.

Full Information

First Posted
November 2, 2015
Last Updated
April 3, 2017
Sponsor
Anthony Iacco
Collaborators
William Beaumont Hospitals
search

1. Study Identification

Unique Protocol Identification Number
NCT02604589
Brief Title
Continuous Intercostal Nerve Blockade for Traumatic Rib Fractures
Official Title
Prime "Rib" Time: Randomized Control Trial Evaluating the Use of Continuous Intercostal Nerve Blockade for Traumatic Rib Fractures
Study Type
Interventional

2. Study Status

Record Verification Date
April 2017
Overall Recruitment Status
Terminated
Why Stopped
resource reallocation
Study Start Date
March 2016 (undefined)
Primary Completion Date
November 2016 (Actual)
Study Completion Date
November 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Anthony Iacco
Collaborators
William Beaumont Hospitals

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Rib fractures are common injuries in accident patients and can be associated with significant pain during recovery. If poorly controlled, pain from splinting due to rib fractures can result in difficulty in breathing leading to incomplete expansion of lung, and even the need to put a patient on a ventilator to help them breathe. Therefore, pain control is critical in managing patients with rib fractures. To date, many studies have shown the effectiveness of continuous intercostal nerve blockade (a slow release of pain medications at the site of injury that prevents the transmission of pain signals). This approach has never been studied in a randomized fashion in rib fracture patients, and has never been compared to patient-controlled narcotic pain medication, commonly used at many hospitals. The purpose of this study is to evaluate the effectiveness of the placement of an elastomeric infusion pump (a small, external, wearable balloon used to deliver medication over time) attached to a continuous infusion catheter or "soaker" catheter (a tube which releases the pain medication through tiny holes in it, right at the site of injury) to deliver local anesthetic medication to reduce pain caused by two or more rib fractures.
Detailed Description
Treatment of rib fractures using an elastomeric infusion pump (a small, external, wearable balloon used to deliver medication over time) containing pain medication and a continuous infusion catheter or "soaker" catheter (a tube which releases the pain medication through tiny holes in it, right at the site of injury) placed in the extrathoracic paraspinous space (a site in the back that is near the broken ribs) to create a continuous intercostal nerve block is relatively novel. Truitt and colleagues have published two studies evaluating the effectiveness of this approach. A pilot study on 30 patients was published in 2010 showing that placement of these catheters was a safe, viable and effective procedure, and resulted in decreased pain scores in rib fracture patients. A second study included 102 patients studied prospectively (from the time of admission to the hospital) comparing epidural anesthesia (an injection of anesthetic into the spine) with local catheter delivery in a non-randomized fashion in 2011. This approach is beginning to be more widely used, but has never been studied in a randomized fashion, and has never been compared to patient-controlled analgesia (PCA, delivery of a pain medication by the push of a button), commonly used at many hospitals. We hypothesize that accident patients with two or more rib fractures who receive pain control through the continuous infusion system will achieve improved pain control in a dose-dependent fashion, improved lung function, and therefore, will require less narcotic pain medication, achieve discharge criteria earlier and have a shorter hospital length of stay in comparison to patients treated with PCA alone.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Rib Fractures
Keywords
Catheters, Indwelling, Infusion Pumps, Anesthesia, Local, Analgesia, Patient-Controlled, Bupivacaine

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Care ProviderOutcomes Assessor
Allocation
Randomized
Enrollment
10 (Actual)

8. Arms, Groups, and Interventions

Arm Title
PCA only
Arm Type
Placebo Comparator
Arm Description
Procedure: Standard of care - Intravenous Patient Controlled Anesthesia (PCA) 0.1 mg hydromorphone hydrochloride, every 6 minutes. Boluses of 0.1 mg IV hydromorphone for uncontrolled pain up to a maximum of 2.5 mg/hr.
Arm Title
Bupivicaine 0.25% (LOW DOSE)
Arm Type
Experimental
Arm Description
Standard PCA infusion 0.1 mg hydromorphone hydrochloride, every 6 minutes. Bolus 0.1 mg hydromorphone for uncontrolled pain up to a maximum of 2.5 mg/hr. Infusion catheter placement. Bupivacaine 0.25% 4 ml/hr total for dual chamber catheter.
Arm Title
Bupivicaine 0.5% (HIGH DOSE)
Arm Type
Experimental
Arm Description
Standard PCA infusion 0.1 mg hydromorphone hydrochloride, every 6 minutes. Bolus 0.1 mg hydromorphone for uncontrolled pain up to a maximum of 2.5 mg/hr. Infusion catheter placement. Bupivacaine 0.5% 4 ml/hr total for dual chamber catheter.
Intervention Type
Drug
Intervention Name(s)
hydromorphone hydrochloride
Other Intervention Name(s)
Dilaudid
Intervention Description
Patient-controlled narcotic analgesia pump
Intervention Type
Procedure
Intervention Name(s)
Infusion catheter placement
Other Intervention Name(s)
OnQ pump placement
Intervention Description
Placement of continuous infusion catheter and elastomeric pump into extrathoracic paraspinous space
Intervention Type
Drug
Intervention Name(s)
bupivicaine 0.25%
Other Intervention Name(s)
Marciane
Intervention Description
Low Dose analgesia
Intervention Type
Drug
Intervention Name(s)
bupivicaine 0.5%
Other Intervention Name(s)
Marcaine
Intervention Description
High dose analgesia
Primary Outcome Measure Information:
Title
Narcotic Use
Description
Quantity of systemic narcotic used (hydromorphone hydrochloride, Dilaudid) averaged per day over the length of hospital stay, in mg/24 hours.
Time Frame
3 days or hospital length of stay, if less than 3 days
Secondary Outcome Measure Information:
Title
Time to Improvement in Pulmonary Function
Description
Determine the impact of catheter-infused medications on maximal inspiratory lung volume measured by incentive spirometer (IS) as a change from baseline at 24, 48, 72 hours and at 3 days post catheter placement or at discharge (or PCA placement in comparator group). Endpoint will be the time to improvement of vital capacity to greater than 1.4 liters (or 15 mL/kg).
Time Frame
3 days or hospital length of stay, if less than 3 days
Title
Time to Improvement in Pain Intensity
Description
Determine the impact of catheter-infused medications on self-reported pain intensity reported as a change from baseline (admission) at 24, 48, 72 hours and at 3 days post catheter placement or at discharge (or PCA placement in comparator group) on a 0-10 point Likert scale, with 0=no pain, and 10= the worst pain ever. Response will be defined as time to a decrease of at least two points on the scale.
Time Frame
3 days or hospital length of stay, if less than 3 days
Title
Morbidity
Description
Collection of complications observed at any point during the hospital admission that included randomization, including pneumothorax, hemothorax, acute respiratory distress syndrome, pneumonia, empyema, need for tracheostomy, need for mechanical ventilation, length of time on mechanical ventilation, and an assessment of the degree of association of each event with the catheter insertion procedure or with underlying trauma. Each of these outcomes will be scored as yes/no.
Time Frame
3 days or hospital length of stay, whichever is longer
Title
Mortality
Description
All cause death, death associated with infusion catheter, within 30 days from date of randomization. This outcome will be scored as yes/no and cause of death will be collected.
Time Frame
30 days
Title
Hospital Length of Stay
Description
Integer days of inpatient admission in the hospital stay that included randomization.
Time Frame
from randomization to discharge, usually within the range of 5-15 days
Title
Surgical Intensive Care Unit (SICU) Length of Stay
Description
Integer days of admission to the surgical intensive care unit. For patients not requiring admission to surgical intensive care, patient is not analyzed. Usual range is 3-5 days.
Time Frame
from admission to Surgical Intensive Care unit to discharge from Surgical Intensive Care Unit

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Admission to trauma service at Beaumont Hospital, Royal Oak, Michigan Two or more rib fractures in an anatomic pattern feasible for nerve blockade (unilateral or bilateral) Age greater than or equal to 18 years Ability to comprehend and endorse an informed consent Exclusion Criteria: Patients who are pregnant or breastfeeding Patients intubated before placement of continuous infusion catheter Any significant concomitant injuries potentially confounding for evaluation of the effectiveness of analgesia (eg., traumatic brain injury) History of an allergic reaction to local anesthetic Use of other regional anesthetics before evaluation (epidural or paravertebral nerve blockade) International Normalized Ratio (INR) > 2.0 Inability to obtain informed consent
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Anthony Iacco, MD
Organizational Affiliation
Beaumont Hospital, Royal Oak MI
Official's Role
Principal Investigator
Facility Information:
Facility Name
Beaumont Hospital - Royal Oak
City
Royal Oak
State/Province
Michigan
ZIP/Postal Code
48073
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
Links:
URL
http://www.beaumont.edu/
Description
Beaumont Health System

Learn more about this trial

Continuous Intercostal Nerve Blockade for Traumatic Rib Fractures

We'll reach out to this number within 24 hrs